UNSPSC 51432808: Enalaprilat dihydrate

This classification denotes an ace inhibitor with the molecular formula C18H24N2O5.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GV0O7ES0R3, chemically known as l-proline, n-((1s)-1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl- but more generally known as enalaprilat, which bears US NIH Compound Identifier 5362032. European Medicines Agency schedules Enalaprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06515MIG.

ENALAPRILAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule enalaprilat dihydrate under HS 29339990. SMILES: C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N[C@@H](CCC2CCCCC2)C(=O)O.O.O.

UNSPSC 51432808 Enalaprilat dihydrate, a Commodity code, encompasses injectable cardiovascular and emergency-response medications supplied to state and local government health systems, emergency medical services, and public health programs. State and local governments procure this and related drugs through a mix of individual municipal purchasing departments, state health and human services agencies, and multistate cooperative purchasing alliances. The work involves supplying pharmaceutical products to emergency departments, fire rescue services, and pharmacy benefit programs with specifications tied to National Drug Codes, expiration-date requirements, and compliance certifications including cGMP, DSCSA, and FDA approval. Issuing bodies range from city-level fire and rescue departments to state HHS commissions and cooperative purchasing entities serving multiple states, with Tampa Fire Rescue and the Texas Health and Human Services Commission appearing in recent activity.

Geographic activity spans Florida, Texas, and Minnesota-Oregon (through MMCAP), though the code's scope is notably broader than the three recent opportunities shown. The City of Tampa's Purchasing Department issued an IFB for Advanced Life Support Medications (Bid No. 26-P-00188) with a response date of April 8, 2026 and an estimated contract value of $40,000, requiring supply of Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue in Hillsborough County; the award carried a 5 percent bid discount for Small Local Business Enterprise participation. The Texas HHS Commission posted an RFI (HHS0017013) on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Department of Administration issued an RFP through MMCAP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products, requiring manufacturers to work with three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and comply with comprehensive insurance, cGMP, and DSCSA requirements; contract pricing was weighted 75 percent on price competitiveness.